Divi's Laboratories Share Price
₹5,881.05 -5.7 (-0.1%)
28 Dec, 2024 01:29
Start SIP in
DIVISLAB
Performance
- Low
- ₹5,870
- High
- ₹5,935
- 52 Week Low
- ₹3,350
- 52 Week High
- ₹6,285
- Open Price₹5,900
- Previous Close₹5,887
- Volume186,225
Investment Returns
- Over 1 Month -3.15%
- Over 3 Month + 9.33%
- Over 6 Month + 29.39%
- Over 1 Year + 52.22%
Smart Investing Starts Here Start SIP with Divi's Laboratories for Steady Growth!
Divi's Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 85
- PEG Ratio
- 2.2
- Market Cap Cr
- 156,123
- P/B Ratio
- 11.5
- Average True Range
- 136.25
- EPS
- 69.16
- Dividend Yield
- 0.5
- MACD Signal
- -13.11
- RSI
- 47.7
- MFI
- 36.51
Divi's Laboratories Financials
Divi's Laboratories Technicals
EMA & SMA
-
- Bullish Moving Average 10
-
- Bearish Moving Average 6
- 20 Day
- ₹5,907.58
- 50 Day
- ₹5,847.61
- 100 Day
- ₹5,571.27
- 200 Day
- ₹5,078.89
Resistance and Support
- R3 5,985.42
- R2 5,960.18
- R1 5,920.62
- S1 5,855.82
- S2 5,830.58
- S3 5,791.02
Divi's Laboratories Corporate Actions - Bonus, Splits, Dividends
Divi's Laboratories F&O
About Divi's Laboratories
Established in 1990, the Indian multinational pharmaceuticals company Divis Laboratories Limited is a manufacturer of active pharmaceutical ingredients (APIs)including generic APIs, Nutraceutical Ingredients, and Custom Synthesis of the APIs providing high-quality products to over 95 countries. It is headquartered in Hyderabad, Telangana, India.
Divis Laboratories is among the world's leading manufacturers of generic APIs, offering a competitive advantage over the entire life cycle of the products. Competent in handling high-potency, high-energy reactions to fulfil the unmet needs of the big pharma customers, Divis Laboratories is the second most valuable pharmaceutical firm in India by market value.
In 1990, Divis Laboratories was founded as Divis Research Centre. Initially, the company began developing commercial techniques for the production of APIs and intermediates. In 1994, Divis Research Centre rebranded as Divis Laboratories Limited to indicate its entry into the API and intermediates manufacturing industry.
1997: The United Kingdom's SGS–Yarsley certifies Divis Laboratories as ISO–9002 compliant.
1999: The European Directorate issues a Certificate of Suitability (CoS) for the Naproxen manufactured by Divis Laboratories.
2001: London's BVQI grants Divis OHSAS–18001 Certification (for its Occupational Health and Safety Management Systems).
2003: Divis inaugurates a new research centre dubbed "DRC–Vizag".
2003: Went for IPO and was listed on the BSE, NSE, and HSE stock markets.
2007: Set up Nutraceuticals facility at Unit 2
2008: The third US-FDA examination of Choutuppal(Unit-1).
2008: The Visakhapatnam(Unit–2) is inspected by the KFDA.
2010: Letter of approval received by Divis Laboratories for the establishment and development of a new pharmaceutical ingredient manufacturing unit in SEZ at Visakhapatnam.
2016: First Anvisa (Brazil) inspection
2020: 8th USFDA inspection at unit 2.
Shareholding Pattern
In addition, public holdings account for 11.3% of the company's equity. The company's equity is held by retail and other investors to the tune of 4.6%.
Corporate Social Responsibility
Corporate Social Responsibility at Divis Laboratories consists of social programs, community service, and environmental impact awareness. Some key initiatives are mentioned below.
Child Empowerment Initiatives-
Promoting Education
Preventive Healthcare
Empowering Women
Safe Drinking water
Swaach Bharat
Healthcare Initiatives-
Free Eye and Dental care Camps
ORT training and pulse polio campaigns
Incentives for Family Planning and awareness campaigns on HIV/ Aids, epidemics and malaria
Initiatives for Development of Village-
Laying of CC Roads in Villages
Construction of underground Drainages in Villages
Construction of Overhead Tanks
Laying of Gravel Roads from villages to Agricultural Fields
Facilitate Street lights in Villages
FINANCIAL INFORMATION
Bottom Line
The profit recorded has grown exponentially from INR 1219 crore to INR 3676 crore in 5 yrs. This is due to a substantial rise in revenue and a decrease in selling, general, and administrative costs.
Net Worth
It has grown by a whopping INR 5668.59 crore over the last 5 yrs.
View More
- NSE Symbol
- DIVISLAB
- BSE Symbol
- 532488
- Managing Director
- Dr. Murali K Divi
- ISIN
- INE361B01024
Similar Stocks to Divi's Laboratories
Divi's Laboratories FAQs
Divi's Laboratories share price is ₹5,881 As on 28 December, 2024 | 01:15
The Market Cap of Divi's Laboratories is ₹156123.4 Cr As on 28 December, 2024 | 01:15
The P/E ratio of Divi's Laboratories is 85 As on 28 December, 2024 | 01:15
The PB ratio of Divi's Laboratories is 11.5 As on 28 December, 2024 | 01:15
Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.
Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.
Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.
Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).
You can easily buy Divis Laboratory shares by registering at 5Paisa and by setting up a Demat account in your name.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.